{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:12:44Z","timestamp":1792512764976,"version":"4.5.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82560696"],"award-info":[{"award-number":["82560696"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004001","name":"Guizhou Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["ZK[2023] 205"],"award-info":[{"award-number":["ZK[2023] 205"]}],"id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004001","name":"Guizhou Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["ZK[2023] 211"],"award-info":[{"award-number":["ZK[2023] 211"]}],"id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017957","name":"Health Commission of Guizhou Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bbcan.2026.189558","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T07:52:43Z","timestamp":1770709963000},"page":"189558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of bladder cancer therapeutic drug clinical trials in mainland China and globally"],"prefix":"10.1016","volume":"1881","author":[{"given":"Jingjing","family":"Kuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongming","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fa","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2026.189558_bb0005","author":"International Agency for Research on Cancer"},{"key":"10.1016\/j.bbcan.2026.189558_bb0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.43198","article-title":"Global disparities of cancer and its projected burden in 2050","volume":"7","author":"Bizuayehu","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.bbcan.2026.189558_bb0015","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41585-022-00578-1","article-title":"Recurrence mechanisms of non-muscle-invasive bladder cancer \u2014 a clinical perspective","volume":"19","author":"Teoh","year":"2022","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2025.03.011","article-title":"Metastasis-directed therapy in the management of urothelial carcinoma: a systematic review and meta-analysis","author":"Miszczyk","year":"2025","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.bbcan.2026.189558_bb0025","author":"Data Bridge Market Research"},{"key":"10.1016\/j.bbcan.2026.189558_bb0030","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10555-009-9192-9","article-title":"Emerging targeted therapies for bladder cancer: a disease waiting for a drug","volume":"28","author":"Dovedi","year":"2009","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bbcan.2026.189558_bb0035","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00345-009-0395-z","article-title":"Economic aspects of bladder cancer: what are the benefits and costs?","volume":"27","author":"Sievert","year":"2009","journal-title":"World. J. Urol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0040","doi-asserted-by":"crossref","first-page":"7268","DOI":"10.3390\/ijms21197268","article-title":"Targeted molecular therapeutics for bladder Cancer\u2014a new option beyond the mixed fortunes of immune checkpoint inhibitors?","volume":"21","author":"Bednova","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189558_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102129","article-title":"Surviving the storm: challenges of bladder cancer care during the COVID-19 pandemic","volume":"22","author":"Vin\u00edcius Suartz","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.bbcan.2026.189558_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.539527","article-title":"Novel combination therapies for the treatment of bladder cancer","volume":"10","author":"Peng","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0055","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189558_bb0060","first-page":"428","article-title":"Trials in drug development and adaptive trial design","volume":"4","author":"Van","year":"2019","journal-title":"JACC: Basic Transl. Sci."},{"key":"10.1016\/j.bbcan.2026.189558_bb0065","doi-asserted-by":"crossref","first-page":"8258","DOI":"10.3390\/ijms25158258","article-title":"Advances in medicine: photodynamic therapy","volume":"25","author":"Aebisher","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189558_bb0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.eururo.2021.03.024","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma: a long-term overall survival and safety update from the Phase 3 IMvigor211 clinical trial","volume":"80","author":"van der Heijden","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0075","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1007\/s10147-024-02583-3","article-title":"Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations","volume":"29","author":"Matsubara","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0080","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1111\/bcp.15233","article-title":"Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy","volume":"88","author":"de Wit","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0085","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2390727","article-title":"A bibliometric analysis of research on PD-1\/PD-L1 in urinary tract tumors","volume":"20","author":"Chen","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.bbcan.2026.189558_bb0090","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12943-024-02095-8","article-title":"Programmed death receptor (PD-)1\/PD-ligand (L)1 in urological cancers\u00a0: the \u201call-around warrior\u201d in immunotherapy","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2026.189558_bb0095","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s11096-023-01667-w","article-title":"Real-world data of atezolizumab in patients with previously treated locally advanced or metastatic urothelial bladder cancer","volume":"46","author":"D\u00edaz Acedo","year":"2024","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.bbcan.2026.189558_bb0100","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2023.03.030","article-title":"Avelumab first-line maintenance therapy for advanced urothelial carcinoma: comprehensive clinical subgroup analyses from the JAVELIN bladder 100 Phase 3 trial","volume":"84","author":"Grivas","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0105","article-title":"Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274","author":"Galsky","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0110","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41585-023-00801-7","article-title":"Turning up the heat: CTLA4 blockade in urothelial cancer","volume":"21","author":"Stockem","year":"2024","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0115","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2318815","article-title":"Immune regulation and the tumor microenvironment in anti-PD-1\/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: a bibliometric analysis","volume":"20","author":"Huang","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.bbcan.2026.189558_bb0120","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.eururo.2022.07.009","article-title":"Phase 1 study of chemoradiotherapy combined with nivolumab \u00b1 ipilimumab for the curative treatment of muscle-invasive bladder cancer","volume":"82","author":"de Ruiter","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0125","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1186\/s12885-024-12652-5","article-title":"Landscape of clinical drug development of ADCs used for the pharmacotherapy of cancers: an overview of clinical trial registry data from 2002 to 2022","volume":"24","author":"Zhou","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2026.189558_bb0130","article-title":"Antibody-drug conjugates in urothelial carcinoma: scientometric analysis and clinical trials analysis","volume":"14","author":"Zhang","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0135","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s11864-023-01114-y","article-title":"Antibody drug conjugates in bladder cancer: current milestones and future perspectives","volume":"24","author":"Alameddine","year":"2023","journal-title":"Curr. Treat. Options in Oncol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0140","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA approval summary: Enfortumab Vedotin for locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Chang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189558_bb0145","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/iju.15368","article-title":"Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: a multicenter observational study","volume":"31","author":"Fukuokaya","year":"2024","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0150","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a Phase II open-label study of Sacituzumab Govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0155","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of Disitamab Vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two Phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111510","article-title":"Human gene therapy: a scientometric analysis","volume":"138","author":"Zhou","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbcan.2026.189558_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1301915","article-title":"Bibliometric analysis of global research trends in adeno-associated virus vector for gene therapy (1991-2022)","volume":"13","author":"Jiang","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0170","doi-asserted-by":"crossref","first-page":"1260498","DOI":"10.3389\/fimmu.2023.1260498","article-title":"Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval","volume":"14","author":"Martini","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0175","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/JU.0000000000004020","article-title":"Efficacy of intravesical Nadofaragene Firadenovec for patients with Bacillus Calmette-Gu\u00e9rin-unresponsive nonmuscle-invasive bladder cancer: 5-year follow-up from a Phase 3 trial","volume":"212","author":"Narayan","year":"2024","journal-title":"J. Urol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0180","doi-asserted-by":"crossref","DOI":"10.1097\/01.JU.0001111604.90306.91.02","article-title":"Final results: Bond-003 cohort C- phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for high-risk bcg-unresponsive non-muscle invasive bladder cancer with carcinoma in situ","author":"Tyson","year":"2025","journal-title":"J. Urol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0185","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1200\/JCO.2025.43.5_suppl.802","article-title":"Preliminary results from LEGEND: a phase 2 study of detalimogene voraplasmid (EG-70), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)","volume":"43","author":"Taylor","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A Phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189558_bb0195","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00345-025-06151-w","article-title":"A systematic review of gene-mediated therapy in BCG-unresponsive NMIBC: emerging evidence and future perspectives","volume":"44","author":"Bertrand","year":"2026","journal-title":"World. J. Urol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17223631","article-title":"Gene therapy for BCG-unresponsive non-muscle invasive bladder cancer: current evidence and future directions","volume":"17","author":"Pinton","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2026.189558_bb0205","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ccell.2020.12.005","article-title":"The landscape of cell and gene therapies for solid Tumors","volume":"39","author":"Wang","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189558_bb0210","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.3390\/ijms22062818","article-title":"Cell therapies in bladder cancer management","volume":"22","author":"Morales","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189558_bb0215","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","article-title":"Non-viral precision T cell receptor replacement for personalized cell therapy","volume":"615","author":"Foy","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189558_bb0220","article-title":"Novel CAR-T cells specifically targeting SIA-CIgG demonstrate effective antitumor efficacy in bladder cancer","volume":"11","author":"Ding","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.bbcan.2026.189558_bb0225","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc4552","article-title":"The microbiome and human cancer","volume":"371","author":"Sepich-Poore","year":"2021","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.bbcan.2026.189558_bb0230","article-title":"Global research trends on the links between gut microbiota and cancer immunotherapy: a bibliometric analysis (2012\u22122021)","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0235","doi-asserted-by":"crossref","DOI":"10.1186\/s12866-024-03372-8","article-title":"Gut microbiota Parabacteroides distasonis enchances the efficacy of immunotherapy for bladder cancer by activating anti-tumor immune responses","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0240","first-page":"22.e13","article-title":"The bladder microbiota is not significantly altered by intravesical BCG therapy","volume":"42","author":"Heidrich","year":"2024","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"10.1016\/j.bbcan.2026.189558_bb0245","article-title":"Bacteria for treatment: microbiome in bladder cancer","volume":"10","author":"K","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbcan.2026.189558_bb0250","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1631\/jzus.B2300392","article-title":"Nano-Bacillus Calmette-Gu\u00e9rin immunotherapies for improved bladder cancer treatment","volume":"25","author":"Zeng","year":"2024","journal-title":"J Zhejiang Univ Sci B"},{"key":"10.1016\/j.bbcan.2026.189558_bb0255","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms10101919","article-title":"BCG vaccine-the road not taken","volume":"10","author":"Dow","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.bbcan.2026.189558_bb0260","article-title":"Past, present and future of Bacillus Calmette-Gu\u00e9rin vaccine use in China","volume":"10","author":"Li","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.bbcan.2026.189558_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110393","article-title":"Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect","volume":"129","author":"Han","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbcan.2026.189558_bb0270","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103329","article-title":"Autoimmune disorders caused by intravesical bacillus Calmette-Guerine treatment: a systematic review","volume":"22","author":"Anis","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.bbcan.2026.189558_bb0280","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: a new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbcan.2026.189558_bb0285","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1038\/s41591-024-03025-3","article-title":"Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial","volume":"30","author":"Li","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189558_bb0290","article-title":"Innovative strategies in genitourinary cancer: the role of oncolytic viruses","volume":"14","author":"Zhang","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0295","article-title":"Opportunities and challenges in applying microbiota to clinical cancer immunotherapy","author":"Jia","year":"2025","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0300","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.2174\/1568026617666170104145640","article-title":"Microtubule targeting agents as cancer chemotherapeutics: an overview of molecular hybrids as stabilizing and destabilizing agents","volume":"17","author":"Tangutur","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189558_bb0305","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41580-020-0214-3","article-title":"The tubulin code and its role in controlling microtubule properties and functions","volume":"21","author":"Janke","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0310","doi-asserted-by":"crossref","DOI":"10.3390\/cells8040346","article-title":"Regulating the BCL2 family to improve sensitivity to microtubule targeting agents","volume":"8","author":"Whitaker","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2026.189558_bb0315","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ctrv.2003.12.005","article-title":"Systemic chemotherapy for patients with bladder cancer \u2013 current controversies and future directions","volume":"30","author":"Chester","year":"2004","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbcan.2026.189558_bb0320","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11864-015-0376-y","article-title":"Chemotherapy for muscle-invasive bladder cancer","volume":"17","author":"Trenta","year":"2016","journal-title":"Curr. Treat. Options in Oncol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0325","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/13543784.2010.496450","article-title":"Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise","volume":"19","author":"Zachos","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bbcan.2026.189558_bb0330","article-title":"Changing landscape of anti-angiogenic therapy: novel approaches and clinical perspectives","volume":"1878","author":"Gacche","year":"2023","journal-title":"Biochim. Biophys. Acta (BBA) - Rev. Cancer"},{"key":"10.1016\/j.bbcan.2026.189558_bb0335","first-page":"1","article-title":"Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective","volume":"7","author":"Yang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2026.189558_bb0340","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020747","article-title":"Novel tyrosine kinase targets in urothelial carcinoma","volume":"22","author":"Torres-Jim\u00e9nez","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189558_bb0345","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12885-018-4059-5","article-title":"Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer","volume":"18","author":"Pulido","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2026.189558_bb0350","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.juro.2014.07.121","article-title":"The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence","volume":"193","author":"Mooso","year":"2014","journal-title":"J. Urol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0355","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41416-023-02513-6","article-title":"Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-bladder 1)","volume":"130","author":"Font","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189558_bb0360","article-title":"Fgfr inhibition in urothelial carcinoma","author":"Li","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0365","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-018-0800-6","article-title":"Targeting tumour microenvironment by tyrosine kinase inhibitor","volume":"17","author":"Tan","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2026.189558_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbcan.2026.189558_bb0375","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ymthe.2018.12.015","article-title":"DANCR promotes metastasis and proliferation in bladder cancer cells by enhancing IL-11-STAT3 signaling and CCND1 expression","volume":"27","author":"Chen","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbcan.2026.189558_bb0380","first-page":"349","article-title":"Protein networking in bladder cancer: immunoreactivity for FGFR3, EGFR, ERBB2, KAI1, PTEN, and RAS in normal and malignant urothelium","volume":"22","author":"R\u00f8tterud","year":"2007","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0385","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/j.clgc.2017.10.011","article-title":"The current status and future role of the phosphoinositide 3 kinase\/AKT Signaling pathway in urothelial cancer: an old pathway in the new immunotherapy era","volume":"16","author":"Liu","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.bbcan.2026.189558_bb0390","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/14728222.2011.645805","article-title":"Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy","volume":"16","author":"Santarpia","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bbcan.2026.189558_bb0395","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ctrv.2015.03.004","article-title":"Molecular biology and targeted therapies for urothelial carcinoma","volume":"41","author":"Seront","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbcan.2026.189558_bb0400","first-page":"1","article-title":"Evolution of the randomized clinical trial in the era of precision oncology","volume":"7","author":"Del Paggio","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102833","article-title":"Outcomes that matter to patients with cancer: living longer and living better","volume":"76","author":"Tregear","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.bbcan.2026.189558_bb0410","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0415","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274","volume":"43","author":"Galsky","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0420","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial\u2606","volume":"36","author":"Powles","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2026.189558_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102376","volume":"23","author":"Matsubara","year":"2025","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.bbcan.2026.189558_bb0430","unstructured":"How Innovative Is China in Biotechnology? ITIF. https:\/\/itif.org\/publications\/2024\/07\/30\/how-innovative-is-china-in-biotechnology\/."},{"key":"10.1016\/j.bbcan.2026.189558_bb0435","doi-asserted-by":"crossref","DOI":"10.1186\/s12992-017-0244-6","article-title":"Obstacles and opportunities in Chinese pharmaceutical innovation","volume":"13","author":"Ni","year":"2017","journal-title":"Glob. Health"},{"key":"10.1016\/j.bbcan.2026.189558_bb0440","series-title":"Chinese biotechs defy funding slump, set sights on global markets","author":"PharmaBoardroom","year":"2024"},{"key":"10.1016\/j.bbcan.2026.189558_bb0445","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/cpt.3676","article-title":"Clinical benefit, trials, and regulatory approval of oncology indications under multiple expedited programs for drug marketing in China, 2018\u20132024","volume":"118","author":"Zhang","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbcan.2026.189558_bb0450","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/cncr.35106","article-title":"Characteristics of clinical trials of new oncology drugs approved in China","volume":"130","author":"Yang","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2026.189558_bb0455","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-025-02267-y","article-title":"Current landscape of innovative drug development and regulatory support in China","volume":"10","author":"Tan","year":"2025","journal-title":"Sig. Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2026.189558_bb0460","article-title":"2024 FDA approvals","author":"Mullard","year":"2025","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:40:47Z","timestamp":1782031247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26000302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0304419X26000302"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189558","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of bladder cancer therapeutic drug clinical trials in mainland China and globally","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189558","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189558"}}